Buy 2C-B-FLY Cas 733720-95-1
Buy 2C-B-FLY Cas 733720-95-1
2C-B-FLY is a psychedelic and designer drug of the phenethylamine, 2C, and FLY families.[4] It was first described in 1995 by Aaron Monte, Professor of Chemistry at UW-La Crosse.[4][5][6]
Use and effects
2C-B-FLY was not included nor mentioned in Alexander Shulgin‘s 1991 book PiHKAL (Phenethylamines I Have Known and Loved).[7] In his subsequent 2011 book The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds however, he listed 2C-B-FLY’s dose as 2.5 to 10 mg orally.[1][2] On the other hand, other sources give 2C-B-FLY’s typical dose range as 10 to 20 mg orally.[3][4][8] The duration of 2C-B-FLY is said to be 6 to 10 hours but up to 20 hours.[4] The effects of 2C-B-FLY have been reported to include euphoria, enhanced interpersonal communication, improved mood, closed- and open-eye visuals such as brightening of colors and visual hallucinations, feelings of insight, stimulation, tactile enhancement, sexual enhancement, and altered time perception.[4][9][10] Other reported effects include pupil dilation, muscle twitching, restlessness, tachycardia, and body temperature changes.[4]
Toxicity
The toxicity of 2C-B-FLY in humans is unknown. Two deaths occurred in October 2009, in Denmark and the United States, after ingestion of a substance that was sold as 2C-B-FLY in a small-time RC shop, but in fact consisted of Bromo-DragonFLY contaminated with a small amount of unidentified impurities.[11]
Interactions
Pharmacology
Pharmacodynamics
| Target | Affinity (Ki, nM) |
|---|---|
| 5-HT1A | 147–350 |
| 5-HT1B | 185 |
| 5-HT1D | 1.4 |
| 5-HT1E | 110 |
| 5-HT1F | ND |
| 5-HT2A | 11–11.6 (Ki) 0.029–53.7 (EC50Tooltip half-maximal effective concentration) 80–104% (EmaxTooltip maximal efficacy) |
| 5-HT2B | 0.9 (Ki) 0.123–40 (EC50) 56–108% (Emax) |
| 5-HT2C | 10.6–12 (Ki) 0.0615–0.149 (EC50) 100–108% (Emax) |
| 5-HT3 | >10,000 |
| 5-HT4 | ND |
| 5-HT5A | >10,000 |
| 5-HT6 | 150 |
| 5-HT7 | 606 |
| α1A | 11,000 |
| α1B | >10,000 |
| α1D | ND |
| α2A | 145–780 |
| α2B | 624 |
| α2C | 233 |
| β1 | >10,000 |
| β2 | >10,000 |
| β3 | ND |
| D1 | 1,400–4,963 |
| D2 | 1,900–6,835 |
| D3 | 6,800 |
| D4 | >10,000 |
| D5 | >10,000 |
| H1 | 3,400–5,753 |
| H2–H4 | >10,000 |
| M1 | 643 |
| M2 | 2,029 |
| M3 | 339 |
| M4 | 520 |
| M5 | 873 |
| I1 | >10,000 |
| σ1 | >10,000 |
| σ2 | >10,000 |
| TAAR1Tooltip Trace amine-associated receptor 1 | 710 (Ki) (mouse) 30 (Ki) (rat) 1,800 (EC50) (mouse) 270 (EC50) (rat) >30,000 (EC50) (human) 49% (Emax) (mouse) 48% (Emax) (rat) |
| SERTTooltip Serotonin transporter | 10,000 (Ki) 73,000 (IC50Tooltip half-maximal inhibitory concentration) (EC50) |
| NETTooltip Norepinephrine transporter | 17,000 (Ki) 97,000 (IC50) (EC50) |
| DATTooltip Dopamine transporter | >26,000 (Ki) 187,000 (IC50) (EC50) |
| MAO-ATooltip Monoamine oxidase A | 19,000 (IC50) |
| MAO-BTooltip Monoamine oxidase B | ND (IC50) |
| Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [12][13][14][15][16][17][18][19] | |
2C-B-FLY is a potent agonist of the serotonin 5-HT2 receptors, including the serotonin 5-HT2A, serotonin 5-HT2B, and serotonin 5-HT2C receptors.[14][15] Unusually among 2C drugs, 2C-B-FLY also shows high affinity for the serotonin 5-HT1D receptor.[14] It also has relatively weak affinity for the serotonin 5-HT1A, 5-HT1B, and 5-HT1E receptors.[14][15] The drug shows biased agonism at the serotonin 5-HT2C receptor.[20]
Chemistry
2C-B-FLY is 8-bromo-2,3,6,7-benzo-dihydro-difuran-ethylamine. The full name of the chemical is 2-(8-bromo-2,3,6,7-tetrahydrofuro[2,3-f] [1]benzofuran-4-yl)ethanamine. It has been subject of little formal study, but its appearance as a designer drug has led the DEA to release analytical results for 2C-B-FLY and several related compounds.
Analogues and derivatives
Analogues of 2C-B-FLY include 2C-B, DOB-FLY, and Bromo-DragonFLY (DOB-DFLY), among others.[4][21][22]
In theory, dihydro-difuran analogs of any of the 2Cx / DOx family of drugs could be made, and would be expected to show similar activity to the parent compounds, 2-CB, DOB, DOM, etc. In the same way that 2C-B-FLY is the dihydro-difuran analog of 2C-B, the 8-iodo equivalent, “2C-I-FLY,” would be the dihydro-difuran analogue of 2C-I, and the 8-methyl equivalent, “2C-D-FLY,” would be the dihydro-difuran analogue of 2C-D.
Other related compounds can also be imagined and produced in which the alpha carbon of the ethylamine sidechain is methylated, giving the amphetamine derivative DOB-FLY, with this compound being the dihydro-difuran analogue of DOB, which can be viewed as the fully unsaturated derivative of Bromo-DragonFLY.
When only one methoxy group of a 2Cx drug is cyclized into a dihydro-furan ring, the resulting compound is known as a “hemifly”, (and these could be termed 2- or 5- “hemis,” depending on where the single dihydro-furan ring is placed). And when an unsaturated furan ring is inserted, the compound is known as a “hemi-dragonfly”. The larger, fully saturated, hexahydro-benzo-dipyran ring derivative has been referred to as “2C-B-MOTH.” The 8-bromo group can also be replaced by other groups to produce compounds such as TFMFly.
A large number of symmetrical and asymmetrical derivatives can be produced by using different combinations of ring systems. Because the 2- and 5- positions (using the common phenylethylamine numbering scheme), the 2- and 5-positions of the benzene ring, if named as benzo-difurans are not equivalent.[clarification needed] Asymmetrical combinations have two possible positional isomers, with different pharmacological activities, at the various 5-HT2 subtypes. These compounds were casually referred to as the “2C-B-GNAT,” and “2C-B-FLEA” compounds, which contain 5 or 6 membered rings at the 2- vs. 5-positions, respectively. Isomeric “Ψ“-derivatives with the oxygens positioned at the 2,6- positions, and mescaline analogues with the oxygens at 3,5- have also been made, but both are less potent than the corresponding 2,5- isomers.[23][24] The symmetrical aromatic benzodifuran derivatives tend to have the highest binding affinity at 5-HT2A, but the saturated benzodifuran derivatives have higher efficacy, while the saturated benzodipyran derivatives are more selective for 5-HT2C. A large number of possible combinations have been synthesised and tested for activity, but these represent only a fraction of the many variations that could be produced.[25][26][27][28][29][30][31][32][33][34][35]
History
2C-B-FLY was first described in the scientific literature by Aaron Phillip Monte and David E. Nichols and colleagues at Purdue University in 1995.[4][5][36] Following its discovery, Alexander Shulgin evaluated 2C-B-FLY.[37][10] It was Ann Shulgin‘s favorite psychedelic drug and she found it particularly enjoyable in terms of enhanced eroticism.[38][37][10][9][39]
Society and culture
Legal status
Canada
As of October 31, 2016; 2C-B-FLY is a controlled substance (Schedule III) in Canada.[40]
Finland
Scheduled in the “government decree on psychoactive substances banned from the consumer market”.[41]
United States
2C-B-FLY is unscheduled and uncontrolled in the United States.[42] However, it may fall under the scope of the Federal Analog Act if it is intended for human consumption given its similarity to 2C-B.
Reviews
There are no reviews yet.